APA (7th ed.) Citation

GYL, L., R, S., FX, S., IN, S., KE, G., C, B., . . . C, G. (2020). BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine, 60, 102988. https://doi.org/10.1016/j.ebiom.2020.102988

Chicago Style (17th ed.) Citation

GYL, Lui, et al. "BET, SRC, and BCL2 Family Inhibitors Are Synergistic Drug Combinations with PARP Inhibitors in Ovarian Cancer." EBioMedicine 60 (2020): 102988. https://doi.org/10.1016/j.ebiom.2020.102988.

MLA (9th ed.) Citation

GYL, Lui, et al. "BET, SRC, and BCL2 Family Inhibitors Are Synergistic Drug Combinations with PARP Inhibitors in Ovarian Cancer." EBioMedicine, vol. 60, 2020, p. 102988, https://doi.org/10.1016/j.ebiom.2020.102988.